



## Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on February 13, 2019

January 25, 2019

### Conference Call and Webcast to Follow

WASHINGTON, Jan. 25, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2018 on Wednesday, February 13, 2019, after the market closes.

Vanda will host a conference call at 4:30 PM ET on Wednesday, February 13, 2019, during which management will discuss the fourth quarter and full year 2018 financial results and other corporate activities. To participate in the conference call, please dial 1-866-688-9426 (domestic) or 1-409-216-0816 (international) and use passcode 1579398.

The conference call will be broadcast simultaneously and archived on Vanda's website, [www.vandapharma.com](http://www.vandapharma.com). Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Wednesday, February 13, 2019, beginning at 7:30 PM ET and will be accessible until Wednesday, February 20, 2019, at 7:30 PM ET. The replay call-in number is 1-855-859-2056 for domestic callers and 1-404-537-3406 for international callers. The passcode number is 1579398.

### **ABOUT VANDA PHARMACEUTICALS INC.:**

Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit [www.vandapharma.com](http://www.vandapharma.com).

### **Investor Contact:**

Jim Kelly  
Executive Vice President & Chief Financial Officer  
Vanda Pharmaceuticals Inc.  
(202) 734-3428  
[jim.kelly@vandapharma.com](mailto:jim.kelly@vandapharma.com)

 View original content: <http://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2018-financial-results-on-february-13-2019-300784301.html>

SOURCE Vanda Pharmaceuticals Inc.